THERAPY DOSSIER · th-d1afd215bc67

Ziprasidone

Drug · Atypical antipsychotic; direct antagonist at 5-HT2A (CHEMBL224), 5-HT2C (CHEMBL225) and dopamine D2 (CHEMBL217) receptors; ATC N05AE04; black box warning TRUE; USAN stem -sidone (1994)

No trauma translation Suggest a correction

This record is classified as “NO TRAUMA TRANSLATION”. Read the indication and notes below for the specific context.

Evidence & regulatory context

Mechanism: Atypical antipsychotic; direct antagonist at 5-HT2A (CHEMBL224), 5-HT2C (CHEMBL225) and dopamine D2 (CHEMBL217) receptors; ATC N05AE04; black box warning TRUE; USAN stem -sidone (1994)
Target: CHEMBL224 (5-HT2A); CHEMBL225 (5-HT2C); CHEMBL217 (dopamine D2)
Injury models: Ischaemia-reperfusion
Reported indication: Not recorded
First approval: 2001
Development stage: Not recorded
ChEMBL record: CHEMBL708 ↗
ChEMBL max phase: 4 / 4 (development scale, not regulatory approval)
Synonyms: CP-88059; Zipradon; Ziprasidona; Geodon; Zeldox; ziprasidone hydrochloride CHEMBL1375743; ziprasidone mesylate CHEMBL3989833
Note: Not recorded

Clinical trials 7

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT02534363 ↗PHASE4completed

Aripiprazole vs Quetiapine vs Ziprasidone in First-episode Non-affective Psychosis

Schizophrenia · Psychotic Disorders

Enrolment: 136 · Results not recorded

NCT02935998 ↗PHASE4unknown

Intramuscular Ziprasidone for Three Days in Patients With Psychotic Agitation

Schizophrenia

Enrolment: 1000 · Results not recorded

NCT01168674 ↗PHASE4completed

Augmentation With Ziprasidone in Major Depressive Disorder

Depression · Bipolar Disorder

Enrolment: 49 · Results not recorded

NCT00237666 ↗PHASE4completed

Open-Label Geodon in Non-Rapid-Cycling Bipolar II Patients With Major Depression

Bipolar II Disorder

Enrolment: 30 · Results not recorded

NCT01211522 ↗PHASE3completed

MIND-USA: Haloperidol vs Ziprasidone vs Placebo for ICU-Associated Neurological Dysfunction

Delirium · Impaired Cognition

Enrolment: 566 · Results not recorded

NCT00215150 ↗PHASE2completed

Ziprasidone for Refractory Social Anxiety Disorder

Social Anxiety Disorder

Enrolment: 51 · Results not recorded

NCT00208559 ↗PHASE2completed

Ziprasidone in Children With Autism: A Pilot Study

Autism

Enrolment: 15 · Results not recorded

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 22627197 ↗2012Reported benefit

Ziprasidone attenuates brain injury after focal cerebral ischemia induced by middle cerebral artery occlusion in rats.

RatIschaemia-reperfusionCerebral (MCAO/stroke)Sprague-DawleyMale5 mg/kg acute; 2.5 mg/kg subchronicAcute treatment at the time of ischemia; subchronic treatment continued for 7 d…

Model: Middle cerebral artery occlusion for 1 h followed by reperfusion

Acute 5 mg/kg and subchronic 2.5 mg/kg ziprasidone significantly reduced infarct size versus vehicle. Acute treatment improved neurological function dose-dependently, and subchronic treatment gave more rapid recovery from functional deficits, prevented severe loss of neuronal marker intensity and a…

Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.78. Machine-extracted fields require source verification.

Loading the evidence…